Solid Lipid Nanoparticles for Enhanced Oral Bioavailability of Valsartan in the Management of Hypertension

Abstract

: Hypertension is a major chronic cardiovascular disorder affecting millions of people worldwide and is a leading cause of heart disease, stroke, and kidney failure. Valsartan, an angiotensin II receptor blocker, is widely used in the management of hypertension; however, its poor water solubility and low oral bioavailability limit its therapeutic effectiveness. Solid Lipid Nanoparticles (SLNs) have emerged as a promising nanocarrier system to overcome these limitations. Valsartan-loaded SLNs enhance drug solubility, improve bioavailability, provide controlled and sustained drug release, and protect the drug from degradation. SLNs are composed of biocompatible and biodegradable lipids, offering advantages such as improved stability, reduced dosing frequency, and enhanced patient compliance. Various preparation methods including hot homogenization, cold homogenization, and solvent emulsification-evaporation, ultra sonication, and microemulsion techniques are used for SLN formulation. Important characterization parameters include particle size, polydispersity index, zeta potential, entrapment efficiency, and in vitro drug release studies. The improved pharmacokinetic and therapeutic performance of valsartan-loaded SLNs makes them a promising approach for effective hypertension management and prevention of associated cardiovascular complications. Future advancements in targeted delivery and large-scale production may further expand their clinical applications.